Global Graft vs Host Disease (GVHD) Treatment Detail Industrial and Market studies 2017-2021
"Global
Graft vs Host Disease (GVHD) Treatment Market 2017-2021"
The Report covers current Industries Trends, Worldwide Analysis,
Global Forecast, Review, Share, Size, Growth, Effect.
Description-
About
Graft vs Host Disease (GVHD) Treatment
Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.
Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.
Get
Sample
Report
With TOC @
http://www.researchmoz.us/enquiry.php?type=S&repid=1300651
Technavios
analysts forecast the global graft vs host disease (GVHD) treatment
market to grow at a CAGR of 7.15% during the period
2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Bristol-Myers Squibb
Novartis
Pfizer
F. Hoffmann-La Roche
Other prominent vendors
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Baxter
Caladrius
Cellular Biomedicine Group
Cipla
Eisai
Eli Lilly
GlaxoSmithKline
Glenmark
Helsinn Healthcare
Heron Therapeutics
Incyte Corporation
IPCA Laboratories
Kadmon Holdings
Lupin
Osiris Therapeutics
RedHill
Sanofi
Shire
Sun Pharmaceutical Industries
Takeda Pharmaceutical
ViaCyte
Market driver
Increased prevalence of cancer
For a full, detailed list, view our report
Market challenge
Off-label use of drugs
For a full, detailed list, view our report
Market trend
Inorganic growth strategies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
Americas
APAC
EMEA
Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
Bristol-Myers Squibb
Novartis
Pfizer
F. Hoffmann-La Roche
Other prominent vendors
Abbott
AbbVie
Allergan
Anterogen
Astellas Pharma
Athersys
Baxter
Caladrius
Cellular Biomedicine Group
Cipla
Eisai
Eli Lilly
GlaxoSmithKline
Glenmark
Helsinn Healthcare
Heron Therapeutics
Incyte Corporation
IPCA Laboratories
Kadmon Holdings
Lupin
Osiris Therapeutics
RedHill
Sanofi
Shire
Sun Pharmaceutical Industries
Takeda Pharmaceutical
ViaCyte
Market driver
Increased prevalence of cancer
For a full, detailed list, view our report
Market challenge
Off-label use of drugs
For a full, detailed list, view our report
Market trend
Inorganic growth strategies
For a full, detailed list, view our report
Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Table
of Contents
PART
01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Market overview
Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by disease type
Acute GVHD
PART 09: Geographical segmentation
GVHD treatment market in Americas
GVHD treatment market in EMEA
GVHD treatment market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
Inorganic growth strategies
Newer applications of bone marrow transplant
Growing focus toward the use of biologics
PART 13: Vendor landscape
Competitive scenario
PART 14: Key vendor analysis
Bristol-Myers Squibb
F. Hoffmann-La Roche
Novartis
Pfizer
Other prominent vendors
PART 15: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Mechanism of GVHD
Exhibit 02: Global GVHD treatment market growth promoters
Exhibit 03: Major acute GVHD symptoms
Exhibit 04: Major chronic GVHD symptoms
Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global GVHD treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules as per vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016
Exhibit 11: Symptoms in acute GVHD
Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions)
Exhibit 13: Symptoms in chronic GVHD
Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions)
Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021
Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016)
Exhibit 24: Various major types of cancers managed by bone marrow transplant
Exhibit 25: Various off-label drugs used in the management of GVHD
Exhibit 26: Various symptoms and disorders associated with GVHD
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Market overview
Five forces analysis
PART 07: Pipeline landscape
PART 08: Market segmentation by disease type
Acute GVHD
PART 09: Geographical segmentation
GVHD treatment market in Americas
GVHD treatment market in EMEA
GVHD treatment market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
Market drivers
Market challenges
PART 12: Market trends
Inorganic growth strategies
Newer applications of bone marrow transplant
Growing focus toward the use of biologics
PART 13: Vendor landscape
Competitive scenario
PART 14: Key vendor analysis
Bristol-Myers Squibb
F. Hoffmann-La Roche
Novartis
Pfizer
Other prominent vendors
PART 15: Appendix
List of abbreviations
List of Exhibits
Exhibit 01: Mechanism of GVHD
Exhibit 02: Global GVHD treatment market growth promoters
Exhibit 03: Major acute GVHD symptoms
Exhibit 04: Major chronic GVHD symptoms
Exhibit 05: Global GVHD treatment market 2016-2021 ($ millions)
Exhibit 06: Opportunity analysis in global GVHD treatment market
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline molecules as per vendors
Exhibit 09: Key clinical trials
Exhibit 10: Segmentation of global GVHD treatment market by disease type 2016
Exhibit 11: Symptoms in acute GVHD
Exhibit 12: Global acute GVHD treatment market 2016-2021 ($ millions)
Exhibit 13: Symptoms in chronic GVHD
Exhibit 14: Global chronic GVHD treatment market 2016-2021 ($ millions)
Exhibit 15: Segmentation of global GVHD treatment market by geography 2016 and 2021
Exhibit 16: Segmentation of global GVHD treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Market scenario in Americas
Exhibit 18: GVHD treatment market in Americas 2016-2021 ($ millions)
Exhibit 19: Market scenario in EMEA
Exhibit 20: GVHD treatment market in EMEA 2016-2021 ($ millions)
Exhibit 21: Market scenario in APAC
Exhibit 22: GVHD treatment market in APAC 2016-2021 ($ millions)
Exhibit 23: Percentage distribution of transplants by organ in US (1988-2016)
Exhibit 24: Various major types of cancers managed by bone marrow transplant
Exhibit 25: Various off-label drugs used in the management of GVHD
Exhibit 26: Various symptoms and disorders associated with GVHD
Full
Report @
http://www.researchmoz.us/global-graft-vs-host-disease-gvhd-treatment-market-2017-2021-report.html
Comments
Post a Comment